Arcus Biosciences

ARCUS BIOSCIENCES INC

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Display,Of,Stock,Market,Quotes

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CSTL

EVER

GPUS

ICHR

IMMP

PLTR

RCUS

VRTX

Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Section,Of,A,Financial,Newspaper,Titled,Key,Movers

AIFU

BLMZ

BRCC

CAMP

CDZI

DGLY

ENGS

JBDI

MRIN

NCNA

NITO

PONY

SXTC

TDUP

Why ThredUp Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket

biotech shutter

Health Care

After-Hours Center

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock offering.

Arcus Biosciences Shares Are Down Today: What&#39;s Going On?

Arcus Biosciences Inc

Press Releases

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update

Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting

Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update

Akebia Therapeutics

Ardelyx

ArriVent BioPharma

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Bicara Therapeutics

CareDx

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Geron

Gyre Therapeutics

Immunome

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Nurix Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Spyre Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Morgan Stanley

Goldman Sachs

Wells Fargo

Barclays

HC Wainwright & Co.

Comments

Arcus Biosciences

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell